* Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Pondicherry, India.
Corresponding Author: Dr. Uma Devi S., Department of
Microbiology, Mahatma Gandhi Medical College and Research Institute,
Pillaiyarkuppam, Pondicherry – 607 402. India. Email:
drumadevi@yahoo.co.in
Abstract
Background: Diabetic foot infections are one of the most feared complications of diabetes. This study was
undertaken to determine the common aetiological agents of diabetic foot infections and their in vitro antibiotic susceptibility.
Methods: A
prospective study was performed over a period of one year in a tertiary
care hospital. The aerobic
bacterial agents were isolated and their
antibiotic susceptibility pattern was determined. Members of Enterobacteriaceae were tested for extended spectrum β-lactamase (ESBL) production by
combination disc
method and staphylococcal isolates were
tested for susceptibility to oxacillin by screen agar method.
Results: Klebsiella pneumoniae (20.5%), Pseudomonas aeruginosa (17%), Staphylococcus aureus (17%) and Escherichia coli (14.6%) were the most common aetiological agents. Polymicrobial infection was observed in
52% patients. The members of Enterobacteriaceae as well as Pseudomonas spp. and Acinetobacter spp. were
found to be susceptible mainly to amikacin, piperacillin-tazobactam and imipenem. Staphylococcus aureus
and Enterococcus spp. were susceptible mostly to vancomycin, with varying susceptibility to tetracycline.
56% of the isolates belonging to Enterobacteriaceae were producing ESBL and 65.5% of Staphylococcus aureus were methicillin-resistant.
Conclusion: High prevalence of multi-drug resistant pathogens was observed. Amikacin, piperacillintazobactam,
imipenem were active against gram-negative bacilli, while vancomycin was found to be active
against gram-positive bacteria.
Key words: Diabetic foot; infections; anti-bacterial agents; Gram-positive bacteria; Gram-negative bacteria
|
Introduction
Diabetic foot is one of the most feared
complications of diabetes and is the leading cause of
hospitalisation in diabetic patients. Diabetic foot is characterised by several pathological complications
such as neuropathy, peripheral vascular disease,
foot ulceration and infection with or without
osteomyelitis, leading to development of gangrene
and even necessitating limb amputation [1,2].
Diabetic patients have a lifetime risk as high as 25%
for developing foot ulceration [3]. Diabetic ulcers
have 15 to 46 times higher risk of limb amputation
than foot ulcers due to other causes [4]. Every year
more than a million diabetic patients require limb
amputation [1].
The impaired
micro-vascular circulation in patients with diabetic foot limits the
access of phagocytes favouring development of infection [2,5]. Escherichia coli, Proteus spp., Pseudomonas spp., Staphylococcus aureus and Enterococcus spp. are
the most frequent pathogens contributing to
progressive and widespread tissue destruction
[2,5]. Diabetic foot infections are often
polymicrobial [4,5]. Methicillin-resistant Staphylococcus aureus (MRSA) has been commonly
isolated from 10-40% of the diabetic wounds [6,7,8].
The increasing association of multi-drug resistant
(MDR) pathogens with diabetic foot ulcers further
compounds the challenge faced by the physician or
the surgeon in treating diabetic ulcers without
resorting to amputation [9]. Infection with MDR
pathogens is also responsible for the increased
duration of hospitalisation, cost of management, morbidity and mortality of the diabetic patients [5].
Appropriate selection of antibiotics based on the
antibiograms of the isolates from the lesions is most
critical for the proper management of these
infections. Nevertheless, the initial empirical
therapy is often decided based on the knowledge of
the susceptibility profile of the prevalent microbial
flora recovered from the previous cases.
So, this study was performed to determine the
common etiological agents of diabetic foot
infections in a tertiary hospital and their in vitro
susceptibility to routinely used antibiotics. The
prevalence of MDR pathogens in patients with
diabetic foot infections was also studied.
Methods
A prospective study was performed over a period of
one year from September 2008 to August 2009. The
study was conducted at a tertiary care teaching
hospital in Pondicherry, India. All patients with
diabetic foot infections were included in the study.
Processing of specimens- Pus or discharges from
the ulcer base and debrided necrotic tissue were
obtained. The specimens were taken immediately to
the microbiology laboratory and processed without
any delay. The specimens were subjected to Gram
staining and were simultaneously inoculated on
blood agar and Mac Conkey agar for isolation of
o aerobic bacteria. After 24 hours incubation at 37 C,
the bacterial isolates were identified based on
standard bacteriological methods [10].
Antibiotic susceptibility testing- Antibiotic
susceptibility testing was performed by Kirby
Bauer’s disc diffusion method according to Clinical
Laboratory Standards Institute (CLSI) guidelines
[11]. Amoxicillin-clavulanic acid, piperacillintazobactam,
tetracycline, ciprofloxacin,
trimethoprim-sulfamethoxazole, gentamicin,
amikacin, cefuroxime, ceftriaxone and imipenem
were tested for Enterobacteriaceae. Piperacillintazobactam,
ciprofloxacin, gentamicin, amikacin,
netilmicin, ceftazidime and imipenem were tested
for Pseudomonas species. Piperacillin-tazobactam,
tetracycline, ciprofloxacin, trimethoprimsulfamethoxazole,
gentamicin, amikacin,
ceftriaxone, ceftazidime and imipenem were tested
for Acinetobacter species. Penicillin, amoxicillinclavulanic
acid, erythromycin, trimethoprim-sulfamethoxazole,
tetracycline, ciprofloxacin, gentamicin, ceftriaxone and vancomycin were
tested for Staphylococcus species. Penicillin,
erythromycin, tetracycline, ciprofloxacin, high
level gentamicin and vancomycin were tested for Enterococcus species.
MRSA, vancomycin-resistant enterococci (VRE),
Gram-negative bacilli producing ESBL, MDR P.
aeruginosa (resistant to ≥ 3 anti-pseudomonal
classes of antimicrobial agents) and MDR
Acinetobacter spp. (resistant to classes of
antimicrobial agents) are defined as multi-drug
resistant (MDR) pathogens [12,13,14].
Combination disc method using both cefotaxime and
ceftazidime, alone and in combination with
clavulanic acid was performed for detection of
extended spectrum. β-lactamase (ESBL) among
the members of Enterobacteriaceae [15]. Five mm
or more increase in zone of inhibition for either
cefotaxime-clavulanic acid or ceftazidimeclavulanic
acid disc compared to the cefotaxime or
ceftazidime disc respectively was taken as
confirmatory evidence of ESBL production.
Staphylococcus aureus isolates were screened for
methicillin resistance using oxacillin-salt screen
agar containing 6μg/mL oxacillin and 4% NaCl
according to CLSI guidelines [11].
Results
Of the 105 patients with diabetic foot, 84 (80%) were
male and 21 (20%) were female. The age ranged
from 32 to 73 years with mean age being 47 ± 11
years. A total of 171 bacteria were isolated from
these 105 patients. The bacteria isolated from the
diabetic foot ulcers are summarised in Table 1. In 47
(44.8%) patients only one pathogen was isolated,
while in 55 (52.4%) patients more than one pathogen
was isolated (41 were infected with two pathogens,
while 14 had three pathogens). In 3 (2.9%) patients,
no isolate was obtained. Gram-positive organisms
were found as the only isolate in 9 (8.6%) patients,
while 55 (52.4%) patients had only gram-negative
organisms. The remaining 41 patients (39.0%) had
both gram-positive and gram-negative organisms.
The ratio of gram-negative to gram-positive
organisms isolated from diabetic foot ulcers was
2.4:1. Gram-negative bacteria accounted for 70.8%,
while gram-positive bacteria accounted for 29.2%.
Table 1- Bacteria isolated from diabetic foot ulcers
|
S.No. |
Bacteria |
No. of isolates (%) |
|
|
|
|
1. |
Klebsiella pneumoniae |
35 (20.5) |
2. |
Pseudomonas aeruginosa |
29 (17.0) |
3. |
Staphylococcus aureus |
29 (17.0) |
4. |
Escherichia coli |
25 (14.6) |
5. |
Coagulase-negative
staphylococci |
12 (7.0) |
6. |
Proteus mirabilis |
10 (5.8) |
7. |
Enterococcus spp. |
9 (5.3) |
8. |
Citrobacter spp. |
7 (4.1) |
9. |
Proteus vulgaris |
6 (3.5) |
10. |
Acinetobacter spp. |
6 (3.5) |
11. |
Pseudomonas spp. |
2 (1.2) |
12. |
Providencia spp. |
1 (0.6) |
|
|
The sensitivity of the isolated gram-negative
bacteria to commonly used antibiotics is
summarised in Table 2. Majority of isolates of Escherichia coli and Klebsiella pneumoniae were
susceptible to amikacin, piperacillin-tazobactam
and imipenem, but resistant to other antibiotics
tested except amoxicillin-clavulanic acid for which
they were showing variable susceptibility. Similarly,
most of our Proteus spp. were susceptible to
tetracycline, ciprofloxacin, amikacin, ceftriaxone,
piperacillin-tazobactam and imipenem, while being
less susceptible to amoxicillin-clavulanic acid,
trimethoprim-sulfamethoxazole and cefuroxime. However, Proteus mirabilis was relatively more
susceptible than Proteus vulgaris to most
antibiotics. Citrobacter spp. were susceptible to
piperacillin-tazobactam, amikacin, ceftriaxone and
imipenem, but resistant to other antibiotics tested.
Table 2- Sensitivity pattern of Gram negative bacteria isolated from diabetic foot ulcer
Most of the Pseudomonas aeruginosa were
susceptible to piperacillin-tazobactam and imipenem, while they were showing varying
susceptibility to ciprofloxacin, gentamicin,
amikacin and netilmicin. Similarly, majority of Acinetobacter spp. were susceptible to piperacillintazobactam,
imipenem and trimethoprimsulfamethoxazole,
while being less susceptible to
gentamicin, amikacin, ciprofloxacin, tetracycline,
ceftiaxone and ceftazidime.
The antibiotic susceptibility patterns of the grampositive
bacteria isolated from diabetic ulcers are
shown in Table 3. Staphylococcus aureus were most
often susceptible to erythromycin, tetracycline and
vancomycin, but were relatively less susceptible to
amoxicillin-clavulanic acid, trimethoprimsulfamethoxazole,
ciprofloxacin, gentamicin and ceftriaxone. None of the Staphylococcus aureus were susceptible to penicillin. Most of the Enterococcus spp. were susceptible only to
vancomycin. However they showed varying
susceptibility to tetracycline, penicillin, and
ciprofloxacin. High-level aminoglycoside resistance was observed in 33% of the Enterococcus spp.
Table 3- Sensitivity pattern of Gram positive bacteria isolated from diabetic foot ulcer
Nineteen of the 29 (65.5%) Staphylococcus aureus were resistant to oxacillin and were therefore
considered as methicillin resistant Staphylococcus aureus (MRSA). ESBL production was detected in 47
of the 84 (56%) isolates belonging to
Enterobacteriaceae. Proteus spp. (10 out of 16
isolates, 62.5%), Klebsiella pneumoniae (21 out of
35 isolates, 60%) and Escherichia coli (14 out of 25
isolates, 56%) were frequently ESBL producers.
Twenty two multi-drug resistant non-fermenting
gram-negative bacteria such as Pseudomonas spp.
and Acinetobacter spp. were observed in our study.
Overall 89 of the 171 (52%) isolates were MDR
pathogens.
Discussion
Diabetic patients often have chronic non-healing
foot ulcers due to several underlying factors such as
neuropathy, high plantar pressures and peripheral
arterial disease [16]. Such chronic long-standing
ulcers are more prone for infection which further
delays the wound healing process. A wide range of
bacteria can cause infection in these patients. In
this study, gram-negative bacteria were the
predominant pathogens, Klebsiella pneumoniae being the commonest aetiological agent, followed
by Pseudomonas aeruginosa and Staphylococcusaureus. Similarly, in two recent studies, gramnegative
bacteria were the commonest agents
[5,7]. But earlier studies have documented grampositive
bacteria as the predominant organisms
associated with diabetic foot infections [17,18].
Therefore, there seems to be a changing trend in the
organisms causing diabetic foot infections, with
gram-negative bacteria replacing gram-positive
bacteria as commonest agents. Polymicrobial
infection was observed in 52% patients, which is
similar to other studies [2,4,7].
The awareness about the antibiotic susceptibility
pattern of the isolates from diabetic foot infections
is crucial for appropriate treatment of cases.
Although in an earlier Indian study, all members of
Enterobacteriaceae were found to be uniformly sensitive to gentamicin and ciprofloxacin [2], in the present study most of them except Proteus spp.
were resistant to these antibiotics. Another recent
study also has reported increasing resistance to
these drugs [5]. Therefore, empirical
use of these
antibiotics in diabetic foot infections should not be
advocated. However, members of Enterobacteriaceae were
found to be susceptible to
amikacin, piperacillin-tazobactam and imipenem.
Similarly, inarecentIndianstudy, Enterobacteriaceae were found to be
sensitive to
ticarcillin-clavulanic acid, cefoperazone-sulbactam
and imipenem [5]. So, empirical treatment of
diabetic foot infections in areas with increased drug
resistance should include a combination of these
antibiotics.
Increased resistance to cefuroxime and ceftriaxone
was noted among the Klebsiella pneumoniae andEscherichia coli isolated in the study group.
Although production of ESBL can explain the
resistance in many of the isolates, but some of the
resistant isolates did not produce ESBL. Production
of other enzymes such as AmpC β-lactamases,
capable of hydrolysing the extended-spectrum
cephalosporins (cefuroxime, cefotaxime,
ceftriaxone, ceftazidime) could be the reason for
resistance in non-ESBL producing isolates [19].
In the present study, Proteus spp. were susceptibile
to ceftriaxone but were often resistant to
cefuroxime, a second generation cephalosporin.
This could be explained by the fact that Proteus spp.
are known to produce unique β-lactamase
(cefuroximase) that has high activity mainly against
cefuroxime and cefotaxime [20].
It was observed that 56% of the members of
Enterobacteriaceae were producing ESBL. Similarly,
Gadepalli et al also have documented ESBL
production in 44.7% of bacterial isolates [5]. ESBL
producers are resistant to all extended-spectrum
cephalosporins and aztreonam regardless of the
susceptibility testing results. Imipenem and
piperacillin-tazobactam are the drugs of choice for
successful control of such ESBL producers.
Staphylococcus aureus isolates in our study were
found to be uniformly susceptible to vancomycin,
but were often resistant to most other antibiotics
except tetracycline and erythromycin. Moreover
65.5% of them were MRSA. This is very high
compared to various other studies on diabetic foot infections which have reported only 10 – 44% MRSA
[5,6,7,8]. Most of the Enterococcus spp. were
susceptible only to vancomycin, though they
showed varying susceptibility to other antibiotics.
Similarly, in another study all enterococcal isolates
were noted to be uniformly susceptible to
vancomycin and linezolid [5]. Hence, vancomycin
can be considered as an important drug in the
empirical regimen for treatment of diabetic foot
infections especially in settings with high resistance
to other antibiotics.
In the present study 52% isolates were MDR
pathogens. Earlier studies on diabetic foot
infections reported 20 - 40% of the isolates to be
multi-drug-resistant [7]. Most of the patients
attending our tertiary care hospital have already
been partially treated at various other centres and
therefore exposed to several antibiotics. In
addition, the widespread use of broad-spectrum
antibiotics, could have contributed to the high
prevalence of MDR pathogens. Similarly, in a recent
study from another tertiary care hospital in India,
72% of the patients with diabetic ulcers were found
to be infected with MDR organisms [5].
The main limitation of this study is the failure to
detect the anaerobic bacteria. Moreover, the risk
factors for the occurrence of MDR pathogens and the
production of AmpC β-lactamases and metallo-β-
lactamases have not been studied.
A combination regimen consisting of amikacin,
piperacillin-tazobactam or imipenem and
vancomycin seems to be the most prudent empirical
treatment of diabetic foot infection. This empirical
therapy can be later modified appropriately based
on the antibiogram of the isolates from the
individual patients.
Key Points
- Diabetic foot infections are often caused by
gram-negative bacteria. Polymicrobial
infections are also common. Incidentally, only
gram-positive bacteria are least likely to be
isolated.
- There is a rising prevalence of MDR pathogens
in diabetic foot infections.
- A combination regimen consisting of amikacin,
piperacillin-tazobactam or imipenem and
vancomycin seems to be an effective
combination for empirical treatment of
diabetic foot infections.
|
References
-
Khanolkar MP, Bain SC, Stephens JW. The
diabetic foot. QJM 2008; 101: 685-95.
-
Anandi C, Alaguraja D, Natarajan V, Ramanathan
M, Subramaniam CS, Thulasiram M, et al.
Bacteriology of diabetic foot lesions. Indian J
Med Microbiol 2004; 22: 175-8.
-
Singh N, Armstrong DG, Lipsky BA. Preventing
foot ulcers in patients with diabetes. JAMA 2005;
293: 217-28.
-
Alavi SM, Khosravi AD, Sarami A, Dashtebozorg A,
Montazeri EA. Bacteriologic study of diabetic
foot ulcer. Pak J Med Sci 2007; 23: 681-4.
-
Gadepalli R, Dhawan B, Sreenivas V, Kapil A,
Ammini AC, Chaudhry R.A clinico-microbiological study of diabetic foot ulcers in
an Indian tertiary care hospital. Diabetes Care
2006; 29: 1727-32.
-
Tentolouris N, Jude EB, Smirnof I, Knowles EA,
Boulton AJ. Methicillin-resistant Staphylococcus
aureus: an increasing problem in a diabetic foot
clinic. Diabet Med 1999; 16:767-71.
-
Shankar EM, Mohan V, Premalatha G, Srinivasan
RS, Usha AR. Bacterial etiology of diabetic foot
infections in South India. Eur J Intern Med 2005;
16: 567-70.
-
Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot
infections. Bacteriology and activity of 10 oral
antimicrobial agents against bacteria isolated
from consecutive cases. Diabetes Care 1996; 19:
638-41.
-
Yoga R, Khairul A, Sunita K, Suresh C.
Bacteriology of diabetic foot lesions. Med J
Malaysia 2006; 61:14-6.
-
Mackie TJ, McCartney JE. Practical medical
microbiology. 14th ed. New York: Churchill
Livingstone; 1996.
-
Clinical Laboratory Standards Institute. Methods
for dilution antimicrobial susceptibility tests for
bacteria that grow aerobically. Approved
standard, 6th ed. CLSI document M7-A6. Wayne,
PA: CLSI; 2005.
-
Siegel JD, Rhinehart E, Jackson M, Chiarello L.
Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant
organisms in healthcare settings, 2006; [cited
2010 Aug 27 ]. Available from :
http://www.cdc.gov/ncidod/dhqp/pdf/ar/md
roGuideline2006.pdf.
-
Hachem RY, Chemaly RF, Ahmar CA, Jiang Y,
Boktour MR, Rjaili GA, et al. Colistin is effective
in treatment of infections caused by multidrugresistant
Pseudomonas aeruginosa in cancer
patients. Antimicrob Agents Chemother 2007;
51: 1905-11.
-
Davis KA, Moran KA, McAllister CK, Gray PJ.
Multidrug-resistant Acinetobacter extremity
infections in soldiers. Emerg Infect Dis 2005; 11:
1218-24.
-
Clinical Laboratory Standards Institute.
Performance standards for antimicrobial disk
susceptibility tests. Approved standard, 9th ed.
CLSI document M2-A9. Wayne, PA: CLSI; 2006.
-
Frykberg RG, Armstrong DG, Giurini J, Edwards
A, Kravette M, Kravitz S, et al. Diabetic foot
disorders: a clinical practice guideline.
American College of Foot and Ankle Surgeons. J
Foot Ankle Surg 2000; 39: S1-60.
-
Mantey I, Hill RL, Foster AV, Wilson S, Wade JJ,
Edmonds ME. Infection of foot ulcers with
Staphylococcus aureus associated with
increased mortality in diabetic patients.
Commun Dis Public Health 2000; 3: 288-90.
-
18. Dang CN, Prasad YD, Boulton AJ, Jude EB.
Methicillin-resistant Staphylococcus aureus in
the diabetic foot clinic: a worsening problem.
Diabet Med 2003; 20: 159-61.
-
Rice LB, Sahm D, Bonomo RA. Mechanisms of
resistance to antibacterial agents. In: Murray
PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken
RH, editors. Manual of clinical microbiology. 8th
ed. Washington, D.C: ASM Press; 2003. p. 1074-101.
-
Senior BW. Proteus, Morganella, and
Providencia. In: Murray PR, Bureau S, Koster J,
Vandenberg L, Pengilley Z, editors. Topley &
Wilson's Microbiology & Microbial infections. 10th
ed. London: Hodder Arnold; 2005. p. 1435-57.